Regenxbio reports Q2 EPS ($1.66), consensus ($1.38)

Reports Q2 revenue $20.0M, consensus $34.5M. “We continue to stay on track advancing our ‘5x’25’ vision to have five gene therapies either on the market or in late-stage development by 2025,” said CEO Kenneth Mills. “We are executing against a transformational year for REGENXBIO, with multiple clinical milestones and updates anticipated in 2023. The encouraging safety and tolerability data for the high-dose cohorts of our in-office wet AMD and DR programs further validate the potential of the suprachoroidal space for AAV delivery to treat chronic retinal diseases. We successfully reached our goal of enrolling patients in CAMPSIITE clinical trial of RGX-121 for treatment of MPS II and reported initial safety results from the first cohort of the AFFINITY DUCHENNE study and expect to present initial efficacy data later this year. Overall, we’re making excellent progress advancing our ‘5x’25’ strategy to bring leading, ground-breaking AAV Therapeutics to patients in need.”